Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.

Science Matters

For the better part of the past decade, computational scientists have been using machine learning to “try to extract value and meaning from data sets that might otherwise be obscure,” in the words of Atul Butte, director of the University of California, San Francisco’s Bakar Computational Health Sciences Institute and chief data scientist for the University of California Health System. A group at the University of California, San Diego (UCSD) has now uncovered such an obscure – and valuable – data set from existing human cancer genomic studies, teasing out diagnostic information from microorganisms that reside inside cancer patients.

Taking sequencing data from samples deposited into The Cancer Genome Atlas (TCGA) project, the researchers showed that microbial signatures derived from sequencing reads from those samples correlate with the emergence and growth of cancer and that the signatures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By 

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.